



EXPANDED MEDICARE PET COVERAGE (eff. April 6, 2009)

*New Additional Coverage indicated in **Bold***

INDICATION	Initial Treatment Strategy (Dx/Staging)	Subsequent Treatment Strategy (Restaging/Monitor Tx)
Brain	Covered	CED
Breast <i>**Diagnosis, Staging <u>Axillary</u> Nodes - NONCOVERED</i>	Covered ²	Covered
Cervical	1 or CED	Covered
Colorectal	Covered	Covered
Esophagus	Covered	Covered
Head & Neck (not Thyroid or CNS)	Covered	Covered
Lung Non-Small Cell	Covered	Covered
Small Cell	Covered	CED
Lymphoma	Covered	Covered
Melanoma <i>** Staging <u>Regional</u> Lymph Nodes - NONCOVERED</i>	3	Covered
Myeloma	Covered	Covered
Ovarian	Covered	Covered
Pancreas	Covered	CED
Prostate	<i>Noncovered</i>	CED
Soft Tissue Sarcoma	Covered	CED
Testicular	Covered	CED
Thyroid	Covered	4 or CED
All other solid tumors	Covered	CED
All other cancers not listed herein	CED	CED

CED – Coverage with Evidence Development will require paperwork similar to NOPR

- 1 Cervical:** **Covered** for the detection of pre-treatment metastases (i.e., staging) in newly diagnosed cervical cancer subsequent to conventional imaging that is negative for extrapelvic metastasis. **CED** for all other uses.
- 2 Breast:** **Covered** for initial staging of metastatic disease
- 3 Melanoma:** All other uses for initial staging are covered.
- 4 Thyroid:** **Covered** for subsequent treatment strategy of recurrent or residual thyroid cancer of follicular cell origin previously treated by thyroidectomy and radioiodine ablation, serum globulin > 10 ng/ml, and negative I-131 whole body scan. **CED** for all other uses for subsequent treatment strategy.